Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -43.91% | 28.74% | -56.95% | 23.87% | -13.36% |
| Total Depreciation and Amortization | -8.94% | 2.08% | -0.15% | -4.23% | -5.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 60.17% | -24.18% | 28.44% | -37.90% | 48.71% |
| Change in Net Operating Assets | -8,773.47% | -98.93% | 351.49% | 61.05% | -345.26% |
| Cash from Operations | -97.34% | -9.19% | 15.56% | 34.78% | -109.29% |
| Capital Expenditure | -6.61% | 26.60% | 48.05% | -146.00% | -513.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.69% | -160.20% | 60.87% | -39.14% | 17.86% |
| Cash from Investing | 32.18% | -161.65% | 64.64% | -40.69% | 17.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 109,500.00% | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 19,709,500.00% | -100.00% | 53,179.62% | -94.67% |
| Foreign Exchange rate Adjustments | -52.44% | -323.13% | -89.91% | 191.40% | 151.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -211.53% | 749.97% | -47.33% | 209.92% | -286.07% |